Cancer Res Treat. 2011;43(3):154-159 Original Article pISSN 1598-2998 eISSN 2005-9256 http://dx.doi.org/10.4143/crt.2011.43.3.154 Open Access Efficacy and Safety of Oxaliplatin, 5-Fluorouracil, and Folinic Acid Combination Chemotherapy as First-Line Treatment in Metastatic or Recurrent Gastric Cancer Han Jo Kim, MD1 Jun Young Eun, MD1 Young Woo Jeon, MD1 Jina Yun, MD2 Kyoung Ha Kim, MD3 Se Hyung Kim, MD2 Hyun Jung Kim, MD2 Sang-Cheol Lee, MD3 Sang Byung Bae, MD1 Chan Kyu Kim, MD2 Nam Su Lee, MD3 Kyu Taek Lee, MD1 Seong-Kyu Park, MD2 Jong-Ho Won, MD3 Dae Sik Hong, MD, PhD2 Hee Sook Park, MD3 1Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Cheonan, 2Divisions of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, 3Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea ++C++orr++esp++on++de++nc++e: ++Da++e S++ik++H++on++g, M++D++, P++hD++ ++ ++ ++ +D+ivi+sio+n o+f H+e+ma+tol+og+y a+nd+O+nc+olo+gy+, + + + + + Department + + + + + of+Internal + + + Medici+ne, + + + Soonchun+hy+an+g + + + + + + + + + + + + + + + + + + + + + + + +U+niv+er+sity+B+uc+he+on+Ho+sp+ita+l, J+un+g 1+-d+on+g,+ + + +W+on+m+i-g+u, B+u+cheon+4+20+-76+7,+Ko+re+a + + + + + + + + + + + + + + + + + + + + + + + + + + +Te+l:+82+-32+-6+21+-51+84+ + + + + + + + + + + + +Fa+x:+82+-3+2-6+21+-5+01+8 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +E-+m+ail:+ds+ho+ng+@schm+c.a+c.k+r + + + + + + + + + + +R+ece+iv+ed+A+pri+l5+,2+011+ + + + + + + + + + + ++A++cce++pt++ed++M++ay++24++, 2++01++1 ++ ++ ++ ++ ++ ++ ++ ++ ++ ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Purpose We retrospectively determined the efficacy and safety of the combination of oxaliplatin, 5- fluorouracil (5-FU), and folinic acid (FA) as first-line chemotherapy for patients with metastatic or recurrent gastric cancer. Materials and Methods Between January 2006 and August 2009, 39 patients with histologically-confirmed, me- tastatic or recurrent gastric cancer underwent chemotherapy, and the results were re- trospectively investigated. The chemotherapy regimen consisted of oxaliplatin (100 mg/m2) and FA (200 mg/m2; 2-hour infusion), then 5-FU (2,400 mg/m2; 46-hour continuous infusion) every 2 weeks. Results Thirty-nine patients received a total of 210 treatment cycles. The median number of cycles was 6 (range, 1 to 16). Of the 32 evaluable patients, zero patients achieved a complete re- sponse and 11 patients achieved a partial response (response rate, 28.2%). The median time- to-progression and overall survival were 4.3 months (95% confidence interval [CI], 2.0 to 6.5 months) and 9.8 months (95% CI, 3.5 to 16.0 months), respectively. The main hematologic to- xicity was anemia, which was observed in 119 cycles (56.7%). Grade 3/4 neutropenia was observed in 32 cycles (15.2%). The main non-hematologic toxicity was constipation, which was observed in 91 cycles (46.2%). Peripheral neuropathy occurred in 71 cycles (33.8%); all cases were grade 1 or 2. No treatment-related deaths were reported. Conclusion This study showed that combination chemotherapy with oxaliplatin, 5-FU, and FA is an active and well-tolerated regimen as first-line treatment in patients with metastatic or recurrent gastric cancer. Key words Stomach neoplasms, Drug therapy, Oxaliplatin 154 Copyright 2011 by the Korean Cancer Association This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/ licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. http://www.cancerresearchandtreatment.org http://www.e-crt.org